Botulinum Toxin Market Analysis By Type (Botulinum Toxin Type A, Botulinum Toxin Type B), By End Use (Therapeutic, Aesthetic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2013 - 2025

  • ID: 4076506
  • Report
  • Region: America, Asia, Asia Pacific, Europe, North America, United States
  • 90 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Allergan Inc.
  • Ipsen group
  • Medytox Inc.
  • Merz GmbH and Co. KGaA
  • US Worldmed, LLC
  • MORE

The global botulinum toxin (BNT) market is expected to reach a value of USD 7.3 billion by 2025. The constant introduction of innovative products for enhancement of aesthetic appeal supporting minimally invasive aesthetic treatments is the prime factor driving the growth of the market.

In addition, rapid growth of the sector is attributed to the rising demand for minimally invasive or non-invasive procedures. These procedures provide advantages such as small incision, shorter hospital stay and rapid wound healing, and hence lead to larger acceptance and demand. In addition, availability of wide variety of minimally invasive or non-invasive treatment options is pushing the global botulinum toxin market towards growth.

Also, the successful completion of research projects is expected to expand the applications of presently approved products. Companies are trying to widen the application of botulinum toxin in therapeutic area through various research activities. For instance, Botox by Allergan received the U.S. FDA approval for the treatment of strabismus (crossed eyes) and blepharospasm associated with dystonia in 1989. Furthermore, in 2004, Botox was approved by the U.S. FDA for hyperidrosis, cervical dystonia, upper limb spasticity, chronic migraine and urinary incontinence in 2009, 2010 and 2011 respectively. Hence, these factors all together will aid in boosting the growth of BNT sales during the forecast period.

Further Key Findings from the Study Suggest:

  • The rapid adoption of minimally invasive treatment is augmenting the growth of neurotoxins market.
  • The botulinum toxin type A segment accounted for the largest share in 2015 and is also anticipated to be the fastest growing segment during the forecast period
  • In 2015, North America dominated the global space with the largest revenue share owing to high demand for minimally invasive or non-invasive aesthetic treatments
  • Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding anti-wrinkle procedures in India, China, and Japan
  • Major players competing in this market include but are not limited to Allergan, Inc.; Ipsen Group; Merz GmbH and Co. KGaA, Medytox,Inc.; US Worldmed, LLC; Lanzhou Institute of Biological Products. Co.Ltd. and Revance Therapeutics, Inc.

The researcher has segmented the botulinum toxin market by type, end use, and region:

Product Type Outlook (Revenue, USD Million; 2013 - 2025)

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

End-Use Outlook (Revenue, USD Million; 2013 - 2025)

  • Therapeutic
  • Aesthetic

Regional Outlook (Revenue, USD Million; 2013 - 2025)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • Asia Pacific
  • China
  • Japan
  • Latin America
  • Mexico
  • Brazil
  • MEA
  • South Africa

PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Inc.
  • Ipsen group
  • Medytox Inc.
  • Merz GmbH and Co. KGaA
  • US Worldmed, LLC
  • MORE

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Snapshot 

Chapter 3. Botulinum Toxin Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Penetration & Growth Prospect Mapping
3.4. SWOT Analysis, By Factor
3.4.1. Political
3.4.2. Economic
3.4.3. Technological
3.5. Industry Analysis – Porter’s

Chapter 4. Botulinum Toxin Market: Type Estimates & Trend Analysis
4.1. Type Movement Analysis & Market Share, 2016 & 2025
4.2. Market Revenue Size & Forecasts and Trend Analyses, 2014 to 2025 (USD Million) for the following type:
4.2.1. Botulinum Type A
4.2.1.1. Botox
4.2.1.2. Dysport
4.2.1.3. Xeomin
4.2.1.4. Others
4.2.2. Botulinum Type B

Chapter 5. Botulinum Toxin Market: End-Use Estimates & Trend Analysis
5.1. End-use Movement Analysis & Market Share, 2016 & 2025
5.2. Market Revenue Size & Forecasts and Trend Analyses, 2014 to 2025 (USD Million) for the following end-use:
5.2.1. Therapeutic
5.2.1.1. Migraine
5.2.1.2. Spasticity
5.2.1.3. Cervical Dystonia
5.2.1.4. Others
5.2.2. Aesthetic

Chapter 6. Botulinum Toxin Market: End-User Estimates & Trend Analysis
6.1. End-user Movement Analysis & Market Share, 2016 & 2025
6.2. Market Revenue Size & Forecasts and Trend Analyses, 2014 to 2025 (USD Million) for the following end-user:
6.2.1. Hospitals & Specialty Clinics
6.2.2. Aesthetic Centers/Clinics

Chapter 7. Botulinum Toxin Market: Regional Estimates & Trend Analysis By Type and End-use 
7.1. Regional Movement Analysis& Market Share, 2016 & 2025
7.2. Market Size & Forecasts and Trend Analyses, 2014 to 2025 (USD Million) for the following Regions/Countries:
7.2.1. North America
7.2.1.1. The U.S.
7.2.1.1.1. The U.S. Botulinum Toxin Market Estimates and Forecast, By Type
7.2.1.1.2. The U.S. Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.1.1.3. The U.S. Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.1.2. Canada
7.2.1.2.1. Canada Botulinum Toxin Market Estimates and Forecast, By Type
7.2.1.2.2. Canada Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.1.2.3. Canada Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.2. Europe
7.2.2.1. Germany
7.2.2.1.1. Germany Botulinum Toxin Market Estimates and Forecast, By Type
7.2.2.1.2. Germany Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.2.1.3. Germany Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.2.2. UK
7.2.2.2.1. UK Botulinum Toxin Market Estimates and Forecast, By Type
7.2.2.2.2. UK Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.2.2.3. UK Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.3.  Asia Pacific
7.2.3.1. Japan
7.2.3.1.1. Japan Botulinum Toxin Market Estimates and Forecast, By Type
7.2.3.1.2. Japan Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.3.1.3. Japan Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.3.2. China
7.2.3.2.1. China Botulinum Toxin Market Estimates and Forecast, By Type
7.2.3.2.2. China Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.3.2.3. China Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.4. Latin America
7.2.4.1. Brazil
7.2.4.1.1. Brazil Botulinum Toxin Market Estimates and Forecast, By Type
7.2.4.1.2. Brazil Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.4.1.3. Brazil Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.4.2. Mexico
7.2.4.2.1. Mexico Botulinum Toxin Market Estimates and Forecast, By Type
7.2.4.2.2. Mexico Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.4.2.3. Mexico Botulinum Toxin Market Estimates and Forecast, By End-user
7.2.5. MEA
7.2.5.1. South Africa
7.2.5.1.1. South Africa Botulinum Toxin Market Estimates and Forecast, By Type
7.2.5.1.2. South Africa Botulinum Toxin Market Estimates and Forecast, By End-use
7.2.5.1.3. South Africa Botulinum Toxin Market Estimates and Forecast, By End-user

Chapter 8. Competitive Landscape
8.1. Strategy Framework
8.2. Company Profiles
8.2.1.  Ipsen group
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Product Benchmarking 
8.2.1.4. Strategic Initiatives
8.2.2. Allergan Inc.
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Product Benchmarking
8.2.2.4. Strategic Initiatives
8.2.3. Medytox Inc.
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Product Benchmarking
8.2.3.4. Strategic Initiatives
8.2.4. Merz GmbH and Co. KGaA
8.2.4.1. Company Overview
8.2.4.2. Product Benchmarking
8.2.4.3. Strategic Initiatives 
8.2.5. US Worldmed, LLC
8.2.5.1. Company Overview
8.2.5.2. Product Benchmarking
8.2.5.3. Strategic Initiatives
8.2.6. Lanzhou Institute of Biological Products Co. Ltd.
8.2.6.1. Company Overview
8.2.6.2. Product Benchmarking
8.2.6.3. Strategic Initiatives
8.2.7. Revance Therapeutics, Inc.
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Product Benchmarking
8.2.7.4. Strategic Initiatives

List of Tables
Table 1 North America Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 2 North America Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 3 North America Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 4 U.S. Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 5 U.S. Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 6 U.S. Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 7 Canada Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 8 Canada Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 9 Canada Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 10 Europe Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 11 Europe Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 12 Europe Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 13 U.K. Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 14 U.K. Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 15 U.K. Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 16 Germany Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 17 Germany Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 18 Germany Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 19 Asia Pacific Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 20 Asia Pacific Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 21 Asia Pacific Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 22 Japan Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 23 Japan Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 24 Japan Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 25 China Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 26 China Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 27 China Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 28 Latin America Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 29 Latin America Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 30 Latin America Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 31 Brazil Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 32 Brazil Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 33 Brazil Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 34 Mexico Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 35 Mexico Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 36 Mexico Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 37 MEA Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 38 MEA Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 39 MEA Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)
Table 40 South Africa Botulinum Toxin Market, By Product Type, 2013 - 2025 (USD Million)
Table 41 South Africa Botulinum Toxin Market, By Type A, 2013 - 2025 (USD Million)
Table 42 South Africa Botulinum Toxin, By End Use, 2013 - 2025 (USD Million)

List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain based sizing & forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market summary
Figure 8 Market trends &outlook
Figure 9 Market segmentation & scope
Figure 10 Market driver relevance analysis (Current & future impact)
Figure 11 Market restraintrelevance analysis (Current & future impact)
Figure 12 Penetration & Growth prospect mapping
Figure 13 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 14 Porter’s Five Forces Analysis
Figure 15 Botulinum Toxin Market Product Outlook Key Takeaways
Figure 16 Botulinum Toxin : Product Type Movement Analysis
Figure 17 Botulinum Toxin Type A Market, 2013 - 2025 (USD Million)
Figure 18 Botox Market, 2013 - 2025 (USD Million)
Figure 19 Dysport Market, 2013 - 2025 (USD Million)
Figure 20 Xeomin Market, 2013 - 2025 (USD Million)
Figure 21 Other Market, 2013 - 2025 (USD Million)
Figure 22 Botulinum Toxin Type B Market, 2013 - 2025 (USD Million)
Figure 23 Botulinum Toxin Market End Use Outlook Key Takeaways
Figure 24 Botulinum Toxin : End Use Movement Analysis
Figure 25 Therapeutic End Use Market, 2013 - 2025 (USD Million)
Figure 26 Aesthetic End Use Market, 2013 - 2025 (USD Million)
Figure 27 Regional Market Place: Key Takeaways
Figure 28 Strategy Framework
Figure 29 Participant Categorization

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ipsen group
  • Allergan Inc.
  • Medytox Inc.
  • Merz GmbH and Co. KGaA
  • US Worldmed, LLC
  • Lanzhou Institute of Biological Products Co. Ltd.
  • Revance Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll